MIAMI, FL — March 3, 2026 — Leads & Copy — Veradermics, Incorporated (NYSE: MANE), a biopharmaceutical company focusing on innovative therapeutics for aesthetic and dermatological conditions, announced that management will participate in investor conferences in March.
Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, at 4:20 p.m. ET in Miami, FL.
Veradermics will also participate in the Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL.
A live webcast of the Leerink conference fireside chat will be available on the “Events” page of the “Investors” section of the Company’s website at ir.veradermics.com. A replay of the webcast will be available for approximately 30 days following the event.
Veradermics is focused on developing therapeutics to address treatment challenges in aesthetic and dermatological conditions. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity.
For additional information, visit www.veradermics.com and follow us on LinkedIn and Instagram.
Source: Veradermics
